Our study was conducted in a retrospective cohort preceding routine anti-PD-1/PD-L1 therapy use in early-stage NSCLC, and as such, it was not possible to determine whether these metabolic parameters could predict response and survival associated with anti-PD-1/PD-L1 treatment. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.